Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. by Andersson, M. et al.
J7ournal ofNeurology, Neurosurgery, and Psychiatry 1994;57:897-902
CONSENSUS
Sahlgrenska Hospital,
Gothenburg, Sweden
M Andersson
Hospital Ramon y
Cajal, Madrid, Spain
J Alvarez-Cermenlo
Instituto Nationale
Neurologico "C.
Besta", Milan, Italy
G Bemardi
Ospedale Civile,
Fidenza, Parma, Italy
I Cogato
Molndal Hospital,
Molndal, Sweden
P Fredman
Gentofte Hospital,
Copenhagen, Denmark
J Frederiksen
Karolinska Institute,
Huddinge, Sweden
S Fredrikson
Institute ofNeurology,
Padua, Italy
P Gallo
San Raffaele Hospital,
Milan, Italy
L M Grimaldi
Institute ofNeurology
and Neurosurgery,
Bergen, Norway
M Gronning
Institute ofNeurology,
London, UK
G Keir
Radboud University
Hospital, Nijmegen,
The Netherlands
K Lamers
Karolinska Institute,
Huddinge, Sweden
H Link
Institute ofNeurology,
Lisbon, Portugal
A Magalhaes
Ospedale Sacro Cuore,
Rome, Italy
A R Massaro
University Hospital,
Linkoping, Sweden
S Ohman
University Neurology
Clinic, Gottingen,
Germany
H Reiber
Sahlgrenska Hospital,
Gothenburg, Sweden
L Ronnback
Centre Hospitalier
Universitaire Vaudois,
Lausanne, Switzerland
M Schluep
H6pital de la
Salpetriere, Paris,
France
E Schuller
Catholic University of
Louvain, Brussels,
Belgium
C J M Sindic
Institute ofNeurology,
London, UK
E J Thompson
University Neurology
Clinic, Barn, Italy
M Trojano
Cerebrospinal fluid in the diagnosis of multiple
sclerosis: a consensus report
M Andersson, J Alvarez-Cermenio, G Bernardi, I Cogato, P Fredman, J Frederiksen,
S Fredrikson, P Gallo, L M Grimaldi, M Gr0nning, G Keir, K Lamers, H Link,
A Magalhaes, A R Massaro, S Ohman, H Reiber, L R6nnback, M Schluep, E Schuller,
C J M Sindic, E J Thompson, M Trojano, U Wurster
Abstract
The Committee of the European
Concerted Action for Multiple Sclerosis
(Charcot Foundation) organised five
workshops to discuss CSF analytical
standards in the diagnosis of multiple
sclerosis. This consensus report from 12
European countries summarises the
results of those workshops. It is hoped
that neurologists will confer with their
colleagues in clinical chemistry to
arrange the best possible local practice.
The most sensitive method for the detec-
tion of oligoclonal immunoglobulin
bands is isoelectric focusing. The same
amounts of IgG in parallel CSF and
serum samples are used and oligoclonal
bands are revealed with IgG specific
antibody staining. All laboratories per-
forming isoelectric focusing should check
their technique at least annually using
"blind" standards for the five different
CSF and serum patterns. Quantitative
measurements of IgG production in the
CNS are less sensitive than isoelectric
focusing. The preferred method for
detection of blood-CSF barrier dysfunc-
tion is the albumin quotient. The CSF
albumin or total protein concentrations
are less satisfactory. These results must
be interpreted with reference to the age
of the patient and the local method of
determination. Cells should be counted.
The normal value is no more than 4
cells/pl. Among evolving optional tests,
measurement of the combined local
synthesis of antibodies against measles,
rubella, and/or varicella zoster could
represent a significant advance if it offers
higher specificity (not sensitivity) for
identifying chronic rather than acute
inflammation. Other tests that may have
useful correlations with clinical indices
include those for oligoclonal free light
chains, IgM, IgA, or myelin basic protein
concentrations.
(7 Neurol Neurosurg Psychiatry 1994;57:897-902)
The clinical diagnosis of multiple sclerosis
can be supported by the use of laboratory
techniques for the analysis of CSF. This
important fact has already been acknow-
ledged by another group of experts.1 We have
refined their notions of "oligoclonal bands or
increased CNS production of IgG" and offer
considered opinions on the relative impor-
tance of different approaches to the study of
CSF immunoglobulins. Specifically, we have
contrasted qualitative (oligoclonal bands)
with quantitative (increased CNS production
of IgG) methods for their sensitivity and
specificity (defined later) in the diagnosis of
multiple sclerosis.
There are, unfortunately, several papers on
multiple sclerosis that do not give sufficient
technical details of the methods used for the
determination of oligoclonal bands or
increased CNS production of IgG. These
techniques must clearly be calibrated by each
individual laboratory. To allow proper inter-
national comparisons, authors should specify
what percentage of patients with clinically
definite multiple sclerosis are positive with
their techniques-that is, the test sensitivity.
They should also state what percentage of
normal or other inflammatory diseases (acute
or chronic) are positive-that is, the test
specificity. These are important because the
percentage will be influenced by the local
prevalence of multiple sclerosis and other
inflammatory diseases.
There is a voluminous literature on CSF
analysis in multiple sclerosis ranging from
more fundamental aspects to reported
changes with treatment. We thus refer to
some selected reviews.2-9 What is of more
practical relevance to the neurologist is the
role of CSF analysis in helping to make the
diagnosis of multiple sclerosis.
Approach to consensus on single topics
Delegates were chosen from most European
countries with an inclination towards those
who had provided a laboratory diagnostic ser-
vice by CSF analysis. The topics discussed
were initially assigned to individual delegates
who each prepared a discussion paper on
their respective topic of interest. It was also
agreed that the relative importance of each
recommendation would be assigned to one of
three categories of tests: (1) an Essential test
is required to support the laboratory basis
for diagnosis of multiple sclerosis; (2)
Complementary tests provide useful additional
information to further support the diagnosis,
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Figure 1 CSF IgG index.
The y axis shows
increasing values for the
quotient ofIgG in
CSF/IgG in serum, and
the x axis shows increasing
values for the quotient of
albumin in CSF/albumin
in serum. The four areas
signify: (1) normal; (2)
local synthesis (normal
barrierfunction); (3) local
synthesis plus abnormal
barrier function; (4)
barrierfunction abnormal
(not local synthesis).
Frequencies of abnormal CSF vanrables in clinically
definite multiple sclerosis
Essential test:
Oligoclonal IgG in CSF (isoelectric focusing) >95%
Complementary tests:
Abnormal blood CSF barrier function 12%
(QAlb > 7 x 10-3)
Increased IgG quotient (IgG index, IgG (local)) 70-80%
Increased cell count >4/pl 50%
and (3) Optional tests are used in some local
centres to provide additional information.
Further work on the optional tests is being
undertaken, however, to try to establish their
eventual role in aiding diagnosis.
In practical terms we worked through three
sequential drafts with each version becoming
successively shorter. The principle of con-
sensus then adopted was that if more than
two people objected, the relevant statement
was dropped. It was not difficult to agree
unanimously on isoelectric focusing but there
were obvious objections to the use of any one
reference as the "chosen" technique. After
much discussion about blood-brain and CSF
barriers and mathematical formulations that
attempt to express quantitative measures of
"CNS production of IgG", all agreed that
these were not essential (as opposed to iso-
electric focusing). There was, however,
almost unanimous agreement on non-linear
formulations, which in practice would be dif-
ferent in various laboratories. Most other
issues were eventually agreed without undue
difficulties.
Diagnosis of multiple sclerosis
The diagnosis of multiple sclerosis is ulti-
mately a clinical decision although examina-
tion of CSF among other paraclinical tests is
an important guide. Perhaps the greatest
attraction of CSF examination is that it can
primarily show an inflammatory origin of
CNS abnormalities.
Of the various tests that can be applied to
CSF, those that detect a humoral immune
response within the CNS are the most impor-
tant in multiple sclerosis. This is because
oligoclonal banding of IgG is reported in
most patients with multiple sclerosis.
Isoelectric focusing is the most sensitive
method for detecting local synthesis when
compared with all other quantitative and
qualitative methods. Local synthesis is not
y
, E
(n
Alb CSF
Alb serum
specific to multiple sclerosis, however, as
there may be oligoclonal bands of IgG in
many other inflammatory neurological dis-
eases. It is considered an essential test,
whereas three others are considered comple-
mentary (table). Some optional tests are also
considered.
Integrated report
When the results of several tests that can give
parallel information are available, these
should be presented in a clinically orientated
report. The clinician may benefit if some
form of quantitative graphical representation
(fig 1) is used for such an integrated report. It
has to be emphasised that the time of lumbar
puncture with respect to the course of the dis-
ease is important for the interpretation of
CSF data. In arriving at consensus for the
graphical representation in fig 1, the following
points were noted as showing an overall
agreement: Laurell subsequently modified his
original plot to show a change in slope rather
than a simple straight line. Reiber and
Felgenhauer devised an empirical fit to yield a
hyperbolic curve, as contradistinct from
Reiber's original straight line(s) model.
Schuller's terms for the relevant areas
are: (2) "inflammatory"; (3) "meningitic";
(4) "transudate". Sindic's term for area (4) is
"mirror". Thompson's term for area (3) is
"greater than".
Single topics
SAMPLE HANDLING AND CELL EXAMINATION
A defined amount (about 10 ml in adults, less
in children) of CSF should be collected in
polypropylene, siliconised glass, or glass tubes
to allow for all tests (table). Cell numbers
should be counted within 30-60 minutes of
lumbar puncture. If the lumbar puncture is
not performed at the same hospital as the
CSF laboratory, the CSF should be trans-
ported to the CSF laboratory as soon as pos-
sible (preferably within six hours) for routine
cytological examination. Differential cell loss
occurs during CSF storage. The number of
white cells in normal CSF is no more than
4/pI.9
Cytological examination is considered a
complementary test in the diagnosis of multi-
ple sclerosis. About 50% of patients with clin-
ically definite multiple sclerosis show a
normal cell count and only 1% of patients
with multiple sclerosis have cell counts of
more than 35/,ul. Cell counts > 35/,ul make
multiple sclerosis unlikely, and thus other
diagnoses should be considered.
Different methods such as cytocentrifuge
or sedimentation chamber can be used for
cytological preparation.'0 The reporting of
CSF cytology to the clinician should be
descriptive including, if possible, considera-
tions of any alternative diagnosis.
EVALUATION OF THE BLOOD-CSF BARRIER
The blood-brain barrier is different from the
blood-CSF barrier. By analysing the protein
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content of lumbar CSF, it is possible to assess
the integrity of the (functionally defined)
blood-CSF barrier, but not the isolated
blood-brain barrier. In healthy people or in
patients without objective signs of neurologi-
cal disorders, the passage of plasma proteins
across the blood-CSF barrier depends on
their hydrodynamic radii, which are related to
their molecular weights under steady state
conditions.1' In such populations the absolute
CSF concentrations of specific plasma
derived proteins depend on many factors
including the serum concentration of each
protein, blood-CSF barrier integrity, rate of
CSF flow, molecular size of the protein, age
of the patient, and the volume of CSF
removed.
Albumin, the major CSF protein, is syn-
thesised only by hepatocytes and is not
catabolised within the CNS. Dynamic studies
with intravenously injected radiolabelled
albumin'2 have shown that serum is the
source of CSF albumin and strongly support
the use of CSF/serum albumin quotients
(QAlb = CSF albumin/serum albumin) to
assess the blood-CSF barrier function.
Another approach'314 is related to the mea-
surement of CSF albumin only: any increase
of CSF albumin (above the mean) indicates
altered blood-CSF barrier function.
Determination of total CSF protein is less
reliable than that of CSF albumin. If total
protein is adopted as an alternative to albu-
min, then the method used should yield a
similar optical density/g protein for both albu-
min and IgG. This is necessary in view of the
wide variability of IgG relative to albumin,
which can vary between 3% in normal and
30% in abnormal CSF. The IgG ratio (CSF
IgG/CSF albumin) is of limited value as a
parallel serum specimen should be analysed
(see later).
The albumin quotient is age dependent.5 16
The upper reference limit for the first 10 ml
of lumbar fluid is 5-0 x 10-3 for patients under
15 years of age; 6-5 x 1 0-3 for patients aged
16-40 years; 8 x 10-3 for patients aged 40-60
years and 8-9 x 1 0-3 for patients over 60
years. Most patients with multiple sclerosis
have values for the albumin quotient below
the upper reference limit. Higher values sug-
gest a different neurological disorder.
Transudated CSF immunoglobulins, as
calculated by a CSF/serum quotient, are not
linearly related to the albumin quotient in
cases with blood-CSF barrier dysfunction.
The use of non-linear formulae or graphs for
the interpretation of IgG values is therefore
recommended (fig 1).
To minimise analytical imprecision, the
CSF and serum concentrations for each par-
ticular protein should be analysed by the
same method and within the same analytical
series.
QUANTIFICATION OF THE HUMORAL IMMUNE
RESPONSE IN THE BRAIN
It is a necessary requirement for any quantita-
tive assay that each laboratory must establish
its own reference range for particular protein
tests.
The detection of a humoral immune
response in the CNS requires an expression
of results that will discriminate between
blood derived and brain derived
immunoglobulin fractions in CSF. Such
quantitative expressions are based on calcula-
tions of the CSF/serum quotients.'2 14 17-19
These quotients are also used for compar-
isons of intrathecal synthesis of all
immunoglobulin classes (IgG, IgA, IgM), as
well as quantitative follow up of intrathecal
antibody synthesis, and calculation of specific
antibody index values (also called antibody
specific activity).
Use of the CSF/serum quotient for IgG
reduces variation due to differences in the
individual concentrations of serum IgG. By
referring this CSF/serum IgG quotient to the
CSF/serum albumin quotient it is possible to
further reduce the variation of the IgG quo-
tient related to individual differences in
blood-CSF barrier function. There are many
approaches by which both of these quotients
are combined to obtain an expression that
will discriminate between the locally synthe-
sised IgG fraction in the brain and the frac-
tion of CSF IgG that is derived from the
blood by filtration.
The use of a non-linear relation between
the IgG quotient and the albumin quotient is
recommended, as a linear approach can lead
to a loss of sensitivity when there is blood-
CSF barrier dysfunction.'9-22 This is especially
true for larger molecules such as IgA or IgM.
If quantitative values are reported, the graphi-
cal representation of the immunoglobulin
quotients (fig 1) as a function of the albumin
quotient is recommended as this gives simul-
taneous information about any local humoral
immune response or any blood-CSF barrier
dysfunctions. Measurements of IgM and IgA
indices are optional tests currently under
study to investigate whether they provide
additional useful information.'423
Another optional test under study is the
detection of intrathecal synthesis of specific
antibodies (for instance, against the measles
virus). These specific antibody tests have
gained further clinical relevance through
improvement of the sensitivity of the evalua-
tion techniques, mainly by the introduction of
extrapolation methods for the locally synthe-
sised fraction of IgG (or IgM), as well as
correction for any blood-CSF barrier dys-
function.'4 24-26 Of special interest for the diag-
nosis of multiple sclerosis is the report that
polyspecific antibody synthesis against several
different viruses can occur in the brain. In
one series, local synthesis of antibody to
measles, rubella, and/or zoster could be found
in the CSF of 94% of patients with multiple
sclerosis.26 The relevance of these methods
has been partially confirmed by the identifica-
tion of oligoclonal patterns on isoelectric
focusing for each virus (measles, rubella,
zoster) by use of the affinity mediated capil-
lary blot technique.27 Also, it has been found
899
 group.bmj.com on February 4, 2014 - Published by jnnp.bmj.comDownloaded from 
Andersson, Alvarez-Cermeno, Bernardi, Cogato, Fredman, Fredeniksen, et al
that the antibody affinity is different in acute
compared with chronic diseases, which fur-
ther supports the idea that the polyspecific
immune response may also become an impor-
tant tool for diagnosis in multiple sclerosis.28
For the correct interpretation of the
humoral immune response in CSF, it is
important to keep in mind that the local IgG,
IgA, or IgM synthesis, including any specific
antibody synthesis in the brain, might have
several origins. It could be due either to a
persistent antibody response from an old clin-
ically irrelevant immunological process or to
an acute inflammatory process. Local IgG
synthesis, detected either by increased IgG
quotients, formulae, or by isoelectric focus-
ing, can still be seen many years after ade-
quately treated cases of neurosyphilis or
neuroborreliosis, among other examples of an
intrathecal immune response.
Figure 2 Diagram showing idealised CSF and serum isoelectric focusing patterns.
Different CSF/serum patterns denote local IgG synthesis. Densitometric scans of the
patterns show the differences in optical density (relative amounts ofprotein per band)
Type 1 is normal. Type 2 is found in multiple sclerosis. Type 3 is found in multiple sc
and brain inflammation in systemic disease-for example, sarcoidosis. Type 4 is foun
systemic inflammation-for example, Guillain-Barre syndrome. Type 5 is found in
myeloma or monoclonal gammopathy of uncertain significance; The pH gradient is ft
6-9 and the cathode is on the right; Poly = polyclonal; Oli = oligoclonal;
Mono = monoclonal.
Figure 3 CSF and serum
isoelectric focusing patterns.
Different CSF/serum
patterns denote local IgG
synthesis. Typical examples
of the five patterns shown
in fig 2. Details are the
same (see legend to fig 2). ~~~~~~~~~~~~~~~~~~~~~~~.
ISOELECTRIC FOCUSING OF OLIGOCLONAL IgG
The strongest consensus is that isoelectric
focusing is the most sensitive test for the
detection of humoral immune responses
when using the same amounts of IgG in par-
allel CSF and serum specimens.1321 27 29-39 The
oligoclonal bands resolved are preferably
visualised by IgG specific antibody staining.
Also, useful information can be obtained con-
cerning other proteins by means of a general
protein stain.
It should be emphasised that the finding of
oligoclonal bands by isoelectric focusing is
not specific for multiple sclerosis. It reaches
its maximal value in differential diagnosis
only when other known causes of CNS
inflammation have been excluded.
The significance of individual bands in
CSF can only be properly understood in the
context of a parallel serum specimen as well
rom as attention to the overall band pattern of all
sample tracks on the isoelectric focusing
plate. Isoelectric focusing can be simply
thought of as separation of IgG on the basis
of different charges or isoelectric points. It is
important to exclude artefactual bands that
are caused by non-linearity of the isoelectric
focusing pH gradient. A good practical indi-
cator for these is to compare the serum pat-
terns from several patients. Bands that are at
1 the same isoelectric point in all specimens of
a given run are most likely to be artefacts pro-
duced by the ampholytes used in the separa-
tion. The higher the number of these
artefactual bands, the more difficult it is to
recognise not only legitimate abnormal serum
bands, but even CSF bands, which can be
p~~y obscured by interference from the common
Xj bands. The choice of commercial source of
ampholytes is more important than the choice
of support media (for example, agarose v
polyacrylamide).
Reports of CSF protein analysis for clini-
cians must always clearly distinguish the facts
from the interpretation and qualitative from
quantitative results. Under "facts" it should
be clear whether the band pattern in CSF is
polyclonal (no bands), monoclonal (parapro-
tein bands), or oligoclonal (few bands).
.:ii.;M.NNf..1
...9.......
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There must be parallel investigation of serum
with a clear comment on the relative band
patterns in CSF and serum. Figures 2 and 3
show examples of the five types of patterns.
The banding patterns on isoelectric focus-
ing shown in figure 2 are simplified for
purposes of demonstration. Densitometric
scanning is not required for interpretation.
Figure 3 gives actual banding patterns as
examples of the five types. Original patterns
are always more clearly visualised than any
photographic reproductions.
For the five types of band patterns, only
patterns 2 and 3 represent local synthesis of
IgG within the CNS. Evaluations are as fol-
lows: (1) normal CSF; (2) CSF restricted
oligoclonal bands: local synthesis; (3) CSF
restricted oligoclonal bands with additional,
identical bands in CSF and serum: local syn-
thesis; (4) identical oligoclonal bands in CSF
and serum: not local synthesis; (5) mono-
clonal bands in CSF and serum: not local
synthesis.
IgA
IgA analysis, either by quantitative or qualita-
tive techniques, is of little value for the labo-
ratory supported diagnosis of multiple
sclerosis.
Strong intrathecal IgA production, how-
ever, may imply a different diagnosis. Most
methods for quantitative analysis of IgA pro-
duction have so far failed to take into account
the relative proportion of monomeric and
dimeric IgA in both CSF and serum,
although dimeric IgA was shown to be prefer-
entially produced in cases of intrathecal syn-
thesis.40 As a consequence, amounts of local
IgA synthesis could be underestimated
depending on the method used. The occur-
rence of oligoclonal IgA bands on isoelectric
focusing in multiple sclerosis or other neuro-
logical diseases is uncommon.'9
IgM
Determination of CSF IgM by quantitative
and qualitative methods to show intrathecal
production of IgM are optional tests for the
diagnosis of multiple sclerosis. The recom-
mended method for qualitative detection of
oligoclonal IgM bands is electrophoresis or
isoelectric focusing of unconcentrated CSF
and subsequent immunodetection.4' Intra-
thecal production has been found, by quanti-
tative and qualitative assays, in only 30% to
60% of patients with multiple sclerosis and
thus seems to be of less value than detection
of oligoclonal IgG bands. A degree of clinical
relevance of IgM estimation has been
reported due to its decrease with duration of
the disease process43 and conversely, being
more common with early exacerbations of the
disease.44 45
Further collaborative work is required to
ascertain correlations between clinical vari-
ables and other CSF indices including myelin
basic protein.29 46
FREE LIGHT CHAINS
In multiple sclerosis, oligoclonal free light
chain bands are seen with about the same fre-
quency as that for oligoclonal IgG bands, and
this detection is a complementary, although
optional, test to establish a laboratory sup-
ported diagnosis.27 Electrophoresis on poly-
acrylamide gel47 or agarose48 are alternative
techniques that can be used to separate free
from bound light chains. After separation,
free light chains are identified by immuno-
staining.
The quantitative determination of free light
chains is critically dependent on the speci-
ficity of the antiserum used.49 Absolute levels
of free K and A light chains are increased in
about 80% and 60% of multiple sclerosis
samples respectively.44 The influence of both
the serum concentrations and of the brain-
CSF barrier on the CSF concentrations are
taken into account by the calculation of index
values.49
QUALITY ASSURANCE
Most of the standards for analytes in diagno-
sis from CSF are defined as method related
values. For internal quality assurance it is
necessary to use a reference material such as
diluted serum or, much better, an accepted
CSF control sample. For detection of preci-
sion a local CSF pool can be used as a daily
control. External quality assessment (CSF
survey) by an external agency is also neces-
sary. The international standardising organi-
sations have cooperated to develop a
harmonised proficiency testing protocol for
CSF.
Analysis of CSF has the advantage that a
CSF/serum quotient can be calculated for
each protein. If CSF and serum protein val-
ues are measured in the same run, the quo-
tient eliminates many of the discrepancies
due to method related calibrations. The
CSF/serum quotient thus approximates to a
method independent value.
The problem of a complicated quality
control in cytology could be solved by send-
ing sets of cytological slide preparations to
different laboratories.
Proficiency testing in CSF analysis should
also consider the control of the quality of data
interpretation by including the five different
focusing patterns50 that have been widely
recognised in our collaborative studies of
"blind" CSF samples (data not shown).
COSTS
The costs vary from around £25 to £90 per
profile for the four tests listed in table 1. There
seem to be three major variables that contrib-
ute to these costs: (1) technician time: beyond
the basic costs for various labour intensive
techniques, there may even be on call pay-
ments-for example, in the case of cell count-
ing; (2) reagents: these are divided mainly
between the more expensive commercial
preparations that are available for the various
tests as opposed to the much more economi-
cal "home-brewed" reagent kits; (3) interpre-
tation: this depends largely on the analyst
having the necessary degree of experience
required to recognise the five basic patterns.
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LETTER
Minor head injury: do you get
what you expect?
Having read the study of Whittaker et al1
concerning expectations and beliefs as
predictors of recovery from minor head
injury, one appreciates that this is an
exciting time in the epidemiological research
of these types of disorders. That is, minor
head injury, whiplash injury, low back pain
and related controversial disorders associated
with chronic pain and disability have long
been approached with a biopsychosocial
model. Furthermore, although more and
more studies, especially in the area of
whiplash, reveal that the bio component is
the least relevant, the ongoing problem has
been to determine where to look for the
psychosocial component. The common and
fertile ground for all these disorders appears
to be patient-held beliefs and, as an aspect of
those beliefs, their expectations. In a longi-
tudinal cohort study of patients with minor
head injury, Whittaker et al found that
patients who believe that their symptoms
have serious negative consequences on their
lives and will continue to do so are at
heightened risk of experiencing signiﬁcant
enduring postconcussional symptoms.
Notably, severity of the postconcussion
symptoms in the initial postinjury period
was not an independent predictor of
outcome. Instead, the interpretation of their
symptoms as serious and enduring is what
puts patients at risk for chronic symptoms.
Parallel results have been found in other
disorders. For individuals with whiplash
injury, for example, in a population-based
cohort of >6000 participants, after adjusting
for the effect of sociodemographic charac-
teristics, postcrash symptoms and pain,
previous health status and collision-related
factors, those who expected to get better
soon recovered more than three times as
quickly (hazard rate ratio 3.62; 95% conﬁ-
dence interval 2.55 to 5.13) as those who
expected that they would never get better.2
Findings were similar for resolution of pain-
related limitations and resolution of neck-
pain intensity. In brief, controlling for initial
pain, symptoms, sex, age and numerous
other baseline variables, the answer to the
single question early after injury “Do you
think that your injury will get better soon;
get better slowly; never get better; or don’t
know?” is a stronger predictor of recovery
rate than any psychosocial variable we have
ever investigated in whiplash cohorts.
Expectations and beliefs also predict the
likelihood of returning to work after whip-
lash injury3 and predict chronicity after low
back injury.4e8
What is most interesting and concerning
about expectations and beliefs that predict
these outcomes is that these expectations
and beliefs are highly prevalent in the general
population, even in those who have not
experienced the disorders before. It has been
shown, for example, that negative beliefs
about neck pain, upper extremity injury and
whiplash injury, in particular, are common in
a Canadian population.9 As well, among
Canadian participants who have themselves
not experienced a minor head injury nor
have an immediate family member who has
had this injury, 50% expect that chronic
symptoms should follow the injury.10
The relevance of this area of research is
further highlighted by the observation that
in countries where a minor head injury has
a much better prognosis than in, say,
Western countries, these expectations are
uncommon or rare.11 12 Whittaker et al are
conducting research on minor head injury in
the direction it needs to go if we are ever to
build a model accurate enough to plan
interventions that will prevent patients from
getting what they expect.
Moreover, Whittaker et al provide clues to
preventive interventions that may improve
outcomes and considerably reduce healthcare
costs in a range of disorders that are common
and costly. Negative beliefs and expectations
for common conditions such as minor head
injury, low back pain and whiplash injury
are highly prevalent and also very expensive.
In Australia, approximately US$10 million
was spent on a social marketing campaign
designed to alter the population beliefs about
low back pain. The program was effective,
and it was cost-effective, with improve-
ments in both population and healthcare
provider beliefs about back pain observed
after the campaign, along with dramatic
reductions in work-related disability and
healthcare visits.13e16
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CORRECTIONS
doi:10.1136/jnnp.57.8.897corr1
Andersson M, Alvarez-Cermeño J, Bernardi
G, et al. Cerebrospinal ﬂuid in the diagnosis
of multiple sclerosis: a consensus report
(J Neurol Neurosurg Psychiatry 1994;57:
897e902). The last ten authors were missing
from the online version of this paper. This
omission has been rectiﬁed and the authors
are now all credited.
doi:10.1136/jnnp.2010.226340.63corr1
ABN Abstracts (J Neurol Neurosurg Psychi-
atry 2010;81:e33. doi:10.1136/jnnp.2010.
226340.63), PAW35 Anti-prion protein
monoclonal antibodies at low doses effec-
tively treat prion disease in mice without
side-effects. In this abstract the author order
was incorrect, it should be C Carswell, R
Drynda, S Martins, A Clarke, S Brandner, S
Mead, J Collinge, A Khalili-Shirazi. Also the
corresponding author is j.collinge@prions.
ucl.ac.uk.
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